Journal Watch · Frontiers in Immunology · 2026

Correlation between PD-L1 expression and clinical pathology, immunobiological markers, and prognosis in gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis.

Large-scale prospective studies are needed for validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251048602.

Zheng Q, Jin S, Xie X et al.Frontiers in Immunology3 min readPharma relevance 85/100

DOI: 10.3389/fimmu.2026.1772011PMID: 41766905Study type: cohort / observational clinical study

TL;DR

Large-scale prospective studies are needed for validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251048602.

Key findings

  • No significant associations were found with sex, age, histological type, tumor stage, invasion, metastasis, CD8+ T cell/FOXP3+ T cell infiltration, or mismatch repair (MMR) status.
  • No publication bias existed.<h4>Conclusion</h4>High PD-L1 expression in GEP-NENs correlates with aggressive clinicopathological features, PD-1 upregulation, and unfavorable prognosis.
  • PD-L1 may serve as a prognostic biomarker and therapeutic target for immune checkpoint inhibitors, particularly in high-grade/poorly differentiated tumors.
  • Large-scale prospective studies are needed for validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251048602.

Numbers at a glance (from the abstract)

95%p<0.001p=0.020

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Two researchers independently extracted data and assessed quality via Newcastle-Ottawa Scale (NOS). Pooled analyses were conducted using Stata 17.0, with odds ratio (OR)/hazard ratio (HR) and 95% confidence interval (CI) as effect indicators, and fixed/random-effects models chosen by heterogeneity.<h4>Results</h4>A total of 22 studies involving 1,872 patients (17 high-quality and 5 moderate-quality) were included. High PD-L1 expression was significantly associated with higher tumor grade (OR = 3.78, 95% CI:2.04-7.01; p<0.001), poorer differentiation (OR = 2.80, 95% CI:1.18-6.65; p=0.020), increased PD-1 expression (OR = 4.15, 95% CI:2.16-7.99; p<0.001), and shorter overall survival (HR = 1.66, 95% CI:1.32-2.10; p<0.001).

Full abstract (original)

Background: <h4>Background</h4>Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have limited therapeutic options. The role of programmed death-ligand 1 (PD-L1) in their clinicopathology, immune markers, and prognosis remains controversial. This meta-analysis aimed to systematically clarify these relationships.<h4>Methods</h4>We searched Medline/PubMed, Web of Science, Embase, and Cochrane Library from inception to November 2025 for studies on PD-L1 expression in GEP-NENs.

What they did: Two researchers independently extracted data and assessed quality via Newcastle-Ottawa Scale (NOS). Pooled analyses were conducted using Stata 17.0, with odds ratio (OR)/hazard ratio (HR) and 95% confidence interval (CI) as effect indicators, and fixed/random-effects models chosen by heterogeneity.<h4>Results</h4>A total of 22 studies involving 1,872 patients (17 high-quality and 5 moderate-quality) were included. High PD-L1 expression was significantly associated with higher tumor grade (OR = 3.78, 95% CI:2.04-7.01; p<0.001), poorer differentiation (OR = 2.80, 95% CI:1.18-6.65; p=0.020), increased PD-1 expression (OR = 4.15, 95% CI:2.16-7.99; p<0.001), and shorter overall survival (HR = 1.66, 95% CI:1.32-2.10; p<0.001).

Results & conclusions: No significant associations were found with sex, age, histological type, tumor stage, invasion, metastasis, CD8+ T cell/FOXP3+ T cell infiltration, or mismatch repair (MMR) status. No publication bias existed.<h4>Conclusion</h4>High PD-L1 expression in GEP-NENs correlates with aggressive clinicopathological features, PD-1 upregulation, and unfavorable prognosis. PD-L1 may serve as a prognostic biomarker and therapeutic target for immune checkpoint inhibitors, particularly in high-grade/poorly differentiated tumors. Large-scale prospective studies are needed for validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251048602.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1772011 · PubMed 41766905.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

Large-scale prospective studies are needed for validation.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251048602.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Two researchers independently extracted data and assessed quality via Newcastle-Ottawa Scale (NOS).

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1772011. PubMed ID: 41766905. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zheng Q, Jin S, Xie X et al.. Correlation between PD-L1 expression and clinical pathology, immunobiological markers, and prognosis in gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1772011.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/correlation-between-pd-l1-expression-and-clinical-pathology-immunobiolog-772011/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides